Arcutis Biotherapeutics announced that ZORYVE (roflumilast) cream received a strong recommendation with high certainty of clinical evidence in the American Academy of Dermatology's first pediatric atopic dermatitis guidelines. The guidelines endorse ZORYVE cream 0.05% for children aged 2-5 and 0.15% for those 6 and older, highlighting its efficacy, safety, and tolerability as a steroid-free topical treatment. This recommendation supports ZORYVE's role in improving disease severity and itch with low discontinuation rates, making it suitable for long-term use in children and adolescents. The guidelines emphasize topical therapies as the cornerstone of managing atopic dermatitis, which affects about 9.6 million children in the U.S., and ZORYVE is recognized for its clinical benefits and favorable safety profile in this population.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
